PER 1.35% 7.5¢ percheron therapeutics limited

For General Information, page-2891

  1. 13,139 Posts.
    lightbulb Created with Sketch. 1376
    Sarepta has far too much Debt !
    Anp will not follow in their footsteps
    Also Sarepta has only 17% of DMD ambulant boys ( yet to provide FDA with efficacy data )
    The point being Boomy
    Anti inflammation drug in combination with a multitude of diseases is a much bigger market .
    Just in the US by 2030 $10 billion for DMD
    Limb Girdle $2 billion
    Asthma $21 billion
    MS $$$?
    whether you like it or not Sarepta is a pathetic comparison:
    Sorry dude






 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.